Therapy
Cure8 research brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Medications. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTherapy
AuthorsO.V. Knyazev Knyazev, M.A. Priymak Priymak, A.V. Kagramanova Kagramanova +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 13, 2026, 12:00 AM
Content availableMetadata only
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Long-Term Safety of Mirikizumab Remains Stable Across UC and Crohn's Disease
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. Open the original article for...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
No new safety risks for upadacitinib in IBD at 3 years; uptick in herpes zoster in Crohn’s
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.